SafeRide Health (SRH) is the new provider for all NEMT rides to doctor appointments and pharmacy visits.
Depending on your needs, rides may include wheelchair-lift-equipped vehicles, stretcher vans, minivans, or ambulatory vans. Please let SRH know what type of ride you need when scheduling.
SafeRide Health (SRH) es el nuevo proveedor de todos los servicios de transporte médico que no son de emergencia (NEMT, por sus siglas en inglés) hacia consultas médicas y farmacias.
Según tus necesidades, los servicios de transporte pueden incluir vehículos con elevador para sillas de ruedas, camionetas con camilla, minivans o camionetas ambulatorias. Por favor, informa a SRH qué tipo de transporte necesitas al programar tu traslado.
Date: September 20, 2022 Attention: All ProvidersEffective Date: December 1, 2022Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated with the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.
Call to action: Effective December 1, 2022, the Health and Human Services Commission (HHSC) will update prior authorization criteria for Adakveo (procedure code J0791). HHSC updated the prior authorization criteria for Adakveo (Crizanlizumab-tmca). The following statement has been removed from the clinical policy and initial prior authorization request:
The client will not receive Adakveo (Crizanlizumab-tmca) therapy concomitantly with voxelotor (Oxbryta)
The following statement has been removed from the clinical policy and renewal/continuation authorization requirements
The client will not receive Adakveo (Crizanlizumab-tmca) therapy concomitantly with Oxbryta (Voxelotor)
How this impacts providers: Prior authorization approval Adakveo (Crizanlizumab-tmca) treatment in clients with sickle cell disease will be considered once all the following criteria are met:
Initial Requests
Initial therapy for Adakveo (crizanlizumab-tmca) may be approved for a 12-month duration if all of thefollowing criteria are met:
Clientmust be 16 years of age or older
Clienthas a diagnosis of sickle cell disease of any genotype
Clienthas experienced two or more vaso-occlusive events in the past 12 months
Renewal or Continuation Therapy
For renewal or continuation therapy, the client must meet all of the following requirements:
Client continues to meet the following initial approval criteria:
Client must be 16 years of age or older
Client has a diagnosis of sickle cell disease of any genotype
Client experienced positive clinical response to therapy as demonstrated by reduced frequency of vaso-occlusive crisis
Client has previously received treatment with Adakveo (crizanlizumab-tmca) without complications
